Stability of plasma metabolomics over 10 years among women

Background: In epidemiological studies, samples are often collected long before disease onset or outcome assessment. Understanding the long-term stability of biomarkers measured in these samples is crucial. We estimated within-person stability over 10 years of metabolites and metabolite features (N=5938) in the Nurses' Health Study (NHS): The primary dataset included 1880 women with 1184 repeated samples donated 10 years apart while the secondary dataset included 1456 women with 488 repeated samples donated 10 years apart. Methods: We quantified plasma metabolomics using two liquid chromatography mass spectrometry platforms (lipids and polar metabolites) at the Broad Institute (Cambridge, MA). Intra-class correlations were used to estimate long-term stability (10 years) of metabolites and were calculated as the proportion of the total variability (within-person + between-person) attributable to between-person variability. Within-person variability was estimated among participants who donated two blood samples approximately 10 years apart while between-person variability was estimated among all participants. Results: In the primary dataset, the median ICC was 0.43 (1st quartile [Q1]: 0.36; 3rd quartile [Q3]: 0.50) among known metabolites and 0.41 (Q1: 0.34; Q3: 0.48) among unknown metabolite features. The most stable (median ICCs: 0.54-0.57) metabolite classes were nucleosides, nucleotides and analogues, phosphatidylcholine plasmalogens, diglycerides, and cholesteryl esters. The least stable (median ICCs: 0.26-0.36) metabolite classes were lysophosphatidylethanolamines, lysophosphatidylcholines and steroid and steroid derivatives. Results in the secondary dataset were similar (Spearman correlation=0.87) to corresponding results in the primary dataset. Conclusion: Within-person stability over 10 years is reasonable for lipid, lipid-related, and polar metabolites, and varies by metabolite class. Additional studies are required to estimate within-person stability over 10 years of other metabolites groups.

[1]  C. Clish,et al.  Circulating amino acids and amino acid-related metabolites and risk of breast cancer among predominantly premenopausal women , 2021, NPJ breast cancer.

[2]  F. Hu,et al.  Branched-Chain Amino Acids and Risk of Breast Cancer , 2020, medRxiv.

[3]  L. Liang,et al.  Mapping the Metabolic Profiles of Long-Term Vegetable, Fruit, and Fruit Juice Consumption , 2020, Current Developments in Nutrition.

[4]  L. Liang,et al.  The Mediterranean diet, plasma metabolome, and cardiovascular disease risk. , 2020, European heart journal.

[5]  E. Karlson,et al.  Circulating plasma metabolites and risk of rheumatoid arthritis in the Nurses' Health Study. , 2020, Rheumatology.

[6]  E. Giovannucci,et al.  A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study , 2020, Metabolites.

[7]  Daniel S. Hitchcock,et al.  A prospective analysis of circulating plasma metabolites associated with ovarian cancer risk. , 2020, Cancer research.

[8]  E. Rimm,et al.  Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men[S] , 2019, Journal of Lipid Research.

[9]  P. Kraft,et al.  Circulating Lysophosphatidylcholines, Phosphatidylcholines, Ceramides, and Sphingomyelins and Ovarian Cancer Risk: a 23-year Prospective Study , 2019, bioRxiv.

[10]  J. Manson,et al.  Metabolic Predictors of Incident Coronary Heart Disease in Women , 2018, Circulation.

[11]  R. Vasan,et al.  Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes , 2017, The Journal of clinical investigation.

[12]  Fabian J Theis,et al.  Computational approaches for systems metabolomics. , 2016, Current opinion in biotechnology.

[13]  B. Rosner,et al.  Plasma carotenoids and risk of breast cancer over 20 y of follow-up. , 2015, The American journal of clinical nutrition.

[14]  C. Clish,et al.  Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α , 2015, Nature Medicine.

[15]  Peter Kraft,et al.  Reproducibility of metabolomic profiles among men and women in 2 large cohort studies. , 2013, Clinical chemistry.

[16]  R. Fortner,et al.  Plasma florescent oxidation products and breast cancer risk: repeated measures in the Nurses’ Health Study , 2013, Breast Cancer Research and Treatment.

[17]  B. Rosner,et al.  A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. , 2013, Cancer research.

[18]  Brian J. Bennett,et al.  Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. , 2013, Cell metabolism.

[19]  Xuehong Zhang,et al.  Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up , 2013, Breast Cancer Research and Treatment.

[20]  E. Rimm,et al.  Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease , 2012, Journal of the American Heart Association.

[21]  R. Glynn,et al.  Interval estimation for rank correlation coefficients based on the probit transformation with extension to measurement error correction of correlated ranked data , 2007, Statistics in medicine.

[22]  S. Hankinson,et al.  Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis , 2006, Cancer Causes & Control.

[23]  S. Hankinson,et al.  Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. , 2006, Cancer research.

[24]  J. Manson,et al.  Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. , 1999, Journal of the National Cancer Institute.